Creative Diagnostics Launches Improved Biosimilar Stable Cell line Products
Shirley, December 16, 2014 (Newswire.com) - Creative Diagnostics, a New York, US-based biotechnology company offering technologies and services for the rapid development of high-performance stable cell lines announced that an expanded offering focusing on the biosimilar market has been launched.
Under the new launch, Creative Diagnostics will offer thousands of stable cell line products, such as Anti-Human ERBB2 MAb Stable Cell Line (Herceptin), Anti-Human CD25 MAb Stable Cell Line (Zenapax), Anti-Human ITGB2 MAb Stable Cell Line (LeukArrest), Anti-RSV MAb Stable Cell Line (Synagis) and Anti-Human CD4 MAb Stable Cell Line (Centara).
With rigorous QC, expertise and accumulated experiences in this industry, Creative Diagnostics scientists have developed many proprietary platforms to improve the production, such as proprietary gene screening and amplification system. As the results already demonstrated, using the proprietary platforms as well as its cell know-how for the rapid development of biosimilars products, the production of biosimilars proteins at levels as much as 50 fold greater than the previous ones.
Dr. Skutsch, staff scientist of Creative Diagnostics, commented:
"We feel it is more and more necessary to offer fully integrated products and services to our client worldwide by including biosimilar expressing cell lines as a globally serving company. With the offer, we have expanded our support of product characterization in order to gain more value on the portfolio".
By employing the proprietary technologies and the know-how industry techniques, Creative Diagnostics can provide top performance cell lines in a well-known and affordable rate.
About Creative Diagnostics
Creative Diagnostics is the pioneer and undisputed global leader in the rapidly emerging market for biosimilars, also known as follow-on biologics (or biopharmaceuticals). We have developed a range of biosimilar stable cell lines using our proprietary gene screening and amplification system. Biosimilar cell lines are grown in suspension and produce high yields of recombinant proteins in chemically defined medium. These manufacturing cell lines have been accepted by CMO's and manufacturers worldwide to produce cGMP.
Contact
Phone: 1-631-624-4882
Email: info@creative-diagnostics.com